Horizon Pharma and SkyePharma have filed a patent infringement lawsuit against Watson Laboratories (WLF) and certain related companies like Actavis Pharma, Andrx and Actavis Inc. The lawsuit was filed in the US District Court for the ...
Tags: Horizon Pharma
Horizon Pharma has announced the issuance of additional notice of allowance from the US Patent and Trademark Office for Rayos (Prednisone) delayed-release tablets. Skyepharma received the notice of allowance for US patent application ...
Tags: Horizon Pharma, Rayos, release tablets
Horizon Pharma RAYOS (prednisone) delayed-release tablets have received the US Food and Drug Administration (FDA) approval. The approved drug is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis ...
Tags: Horizon Pharma RAYOS delayed-release tablets, rheumatoid arthritis, RA
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended SkyePharma's flutiform (fluticasone propionate/formoterol fumarate) for European marketing approval. Flutiform is a ...
Tags: Skyepharma Flutiform, SkyePharma, long-acting beta-agonist